Global Bio-Similars Market Report (2020-2025)
The biosimilars market report analysis the report by bio similar products (Biosimilar Adalimumab, Biosimilar Bevacizumab, Cetuximab Biosimilars, Biosimilar Infliximab, Biosimilar ranibizumab, Biosimilar Rituximab, Biosimilar Trastuzumab, Biosimilar Etanercept, Biosimilar Insulin Lispro, Biosimilar Insulin Glargine, Biosimilar Pegfilgrastim, Biosimilar Teriparatide), by product class (Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and others), by Application, and by Region.
.svg)
Market Snapshot
Market Overview
The pandemic has devastated economic and public health, whereas industry has been busy finding the vaccines and supportive treatments.
Industry has witnessed cross-stakeholder collaboration among academia, industry, and government for various activities such as drug re-purposing projects, antibody discovery programs vaccine research and development, and clinical trial enrollments, especially for COVID-19 patients.
The COVID-19 has long-term impacts for the future biologic industry the same applicable to bio-similar makers.
The developments were majorly witnessed in pharmaceutical industry, However, bio-similar developments were slow with COVID-19.
Some of the key notable developments took place in bio-similar space during the COVID-19 pandemic.
For instance, in March 2020, Samsung Bioepis has announced the approval of a 420mg multi-dose vial of its Herceptin bio-similar Ontruzant, which is cost-effective and promotes less waste. This bio-similar was already approved by the FDA in 2019 as a 150 mgsingle-dose.
In March 2020, Celltrion and Teva have launched their trastuzumab bio-similar Herzuma (trastuzumab-pkrb) inthe US, which can be used to treat breast and gastric cancer and has been approved in Canada.
Segmentation by Product Class
Biosimilars provide opportunity for increased access and reduced costs for patients and healthcare systems.
The key challenge that faced in bio-similar development is that it requires complicated reverse engineering, as biologic drugs exhibit great complexity in molecular and are sensitive to variations in manufacturing and handling.
The market offers opportunities for growth in the development of biosimilars for complex mAb’s. Complex mAb’s are one of the highest selling biologics and used for treating key therapeutics including various cancers and autoimmune disorders such as rheumatoid arthritis.
The bio-similars for complex mAb’s is owing to the increased upcoming patent expiry of top-selling drugs in the biologics.
The competition for these bio-similar is expected to increase with many pharmaceutical companies have entered the rapidly growing mAb biosimilars market.
Segmentation by Geography
The trends in biosimilar share some similarities across develop and emerging markets. Except United States, developed markets show greater presence and manufacturers are mainly focusing on these developed markets.
Developed markets such as Europe, United States and in Japan continue to have major number of bio-similars molecules in development.
The growth in developed markets is mainly due to discounts and incentives from physicians and insurance providers. Whereas in emerging markets biosimilars are still in nascent stage, with little or no presence.
The slow growth is mainly due to lack of access for affordable biosimilars to the patients besides physicians are more open towards low cost therapies.
As treatment rates in emerging markets for flagship biologics are still low compared to developed markets hence the adoption of biosimilars is far behind in these nations.
However,strong growth is expected in most of the emerging markets as well with faster approval processes adopted by nations compared to developing nations
Competitive Landscape
Major Players
Table of Contents
1. Research Methodology and Scope
2. Market Overview
2.1 Approved Biosimilar Products
2.2 Biosimilars Products in Pipeline
2.3 Key Market Developments
3.1 Approved and Pipeline Analysis of Biosimilar Products by Major Companies
3. Market Dynamics
3.1 Drivers
3.2 Restraints
4. Industry Regulations
5. Competitive Landscape
6. Key Biosimilars Products in Development
6.1 Biosimilar Adalimumab
6.2 Biosimilar Bevacizumab
6.3 Cetuximab Biosimilars
6.4 Biosimilar Infliximab
6.5 Biosimilar ranibizumab
6.6 Biosimilar Rituximab
6.7 Biosimilar Trastuzumab
6.8 Biosimilar Etanercept
6.9 Biosimilar Insulin Lispro
6.10 Biosimilar Insulin Glargine
6.11 Biosimilar Pegfilgrastim
6.12 Biosimilar Teriparatide
7. Biosimilar Market Analysis by Product Class
7.1 Monoclonal Antibodies
7.2 Recombinant Hormones
7.3 Immunomodulators
7.4 Anti-inflammatory Agents
7.5 Others
8. Biosimilar Market Analysis by Applications
8.1 Blood Disorders
8.2 Growth Hormonal Disorders
8.3 Chronic and Autoimmune Disorders
8.4 Oncology
8.5 Others
9. Biosimilars Market by Region
9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 United Kingdom
9.2.2 Spain
9.2.3 Italy
9.2.4 Germany
9.2.5 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 India
9.3.3 Japan
9.3.4 Australia
9.3.5 South Korea
9.3.6 Rest of Asia-Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Rest of South America
9.5 Middle East and Africa
10. Company Profiles
10.1 Pfizer
10.2 Eli Lily and Company
10.3 Cellitron Healthcare
10.4 Mylan
10.5 Coherus BioSciences
10.6 Teva Pharmaceuticals
10.7 Sandoz
10.8 Biogen
10.9 Samsung Bioepis
10.10 Amgen
11. Appendix
Research Methodology
